{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-157286","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.551366+00:00","generated_at":"2026-06-14T10:41:45.294223+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"TScan Therapeutics appoints Gavin MacBeath as permanent CEO with increased compensation","bullets":["Gavin MacBeath, Ph.D., appointed CEO and Class I Director effective May 24, 2023; previously acting CEO since March 2023.","Base salary increased to $565,000 (from $470,000); target bonus raised to 50% of base (from 40%).","Received stock option award for 1,121,300 shares at $2.49 per share; contingent on stockholder approval of equity plan amendment.","Board also granted options for 7,403,100 shares aggregate to other recipients, subject to same amendment.","Company highlights progress in hematologic and solid tumor programs, and collaboration with Amgen for Crohn's disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-157286","json":"https://secwatch.observer/filing/0001193125-23-157286.json","markdown":"https://secwatch.observer/filing/0001193125-23-157286.md","text":"https://secwatch.observer/filing/0001193125-23-157286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523157286/0001193125-23-157286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523157286/d515205d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T10:41:45.294223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c9a878294","claim":"Gavin MacBeath was appointed as Director at TScan Therapeutics, Inc..","evidence_excerpt":"appointed Gavin MacBeath, Ph.D., as Chief Executive Officer and member the Board, effective May 24, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523157286/0001193125-23-157286-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"be9b13d487","claim":"Gavin MacBeath was appointed as Chief Executive Officer at TScan Therapeutics, Inc..","evidence_excerpt":"appointed Gavin MacBeath, Ph.D., as Chief Executive Officer and member the Board, effective May 24, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523157286/0001193125-23-157286-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}